Clinical Trials List
2026-04-01 - 2037-12-31
Phase III
Recruiting4
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
- Ya-Ping Chen Division of Hematology & Oncology
- 傅蓓安 Division of Hematology & Oncology
- Ya-Ting Hsu Division of Hematology & Oncology
- 張力常 Division of Hematology & Oncology
- Tsai-Yun Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 林明恩 Division of Hematology & Oncology
- Tai-Chung Huang Division of Hematology & Oncology
- 田豐銘 Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- Chieh-Lung Cheng Division of Hematology & Oncology
- Chien-Chin Lin Division of Hematology & Oncology
- Huai-Hsuan Huang Division of Hematology & Oncology
- HSIN-AN HOU Division of Hematology & Oncology
- CHENG-HONG TSAI Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 吳宜穎 Division of Hematology & Oncology
- 陳昱光 Division of Hematology & Oncology
- 賴學緯 Division of Hematology & Oncology
- 陳宇欽 Division of Hematology & Oncology
- 劉韋農 Division of Hematology & Oncology
- 李卓豪 Division of Hematology & Oncology
- 黃子權 Division of Hematology & Oncology
- 戴明燊 Division of Hematology & Oncology
- 張平穎 Division of Hematology & Oncology
- 葉人華 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
25 participants
-
Global
735 participants
